TMBIM4 and Alzheimer disease: For instance, blarcamesine (Anavex 2-73), a compound targeting S1R and muscarinic receptors, has successfully completed Phase 2/3 clinical trials for Rett syndrome and early-stage Alzheimer’s disease (AD) [8,9].